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Background: Chronic disease management has been implemented for some time in several countries to tackle the
increasing burden of chronic diseases. While Switzerland faces the same challenge, such initiatives have only
emerged recently in this country. The aim of this study is to assess their feasibility, in terms of barriers, facilitators
and incentives to participation.
Methods: To meet our aim, we used qualitative methods involving the collection of opinions of various healthcare
stakeholders, by means of 5 focus groups and 33 individual interviews. All the data were recorded and transcribed
verbatim. Thematic analysis was then performed and five levels were determined to categorize the data: political,
financial, organisational/ structural, professionals and patients.
Results: Our results show that, at each level, stakeholders share common opinions towards the feasibility of chronic
disease management in Switzerland. They mainly mention barriers linked to the federalist political organization as
well as to financing such programs. They also envision difficulties to motivate both patients and healthcare
professionals to participate. Nevertheless, their favourable attitudes towards chronic disease management as well as
the fact that they are convinced that Switzerland possesses all the resources (financial, structural and human) to
develop such programs constitute important facilitators. The implementation of quality and financial incentives
could also foster the participation of the actors.
Conclusions: Even if healthcare stakeholders do not have the same role and interest regarding chronic diseases,
they express similar opinions on the development of chronic disease management in Switzerland. Their overall
positive attitude shows that it could be further implemented if political, financial and organisational barriers are
overcome and if incentives are found to face the scepticism and non-motivation of some stakeholders.
Keywords: Chronic disease, Disease management, Attitude, Patients, Health personnel, Qualitative researchBackground
Chronic diseases are increasing worldwide and are pro-
jected to be the leading causes of deaths and disability in
2030 [1]. To tackle this burden, healthcare systems have
begun to rethink the organization of chronic care, and
several countries have developed chronic disease man-
agement (CDM) initiatives centred on patients’ needs
and based on formal evidence of effectiveness [2-5].* Correspondence: stephanie.lauvergeon@chuv.ch
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distribution, and reproduction in any mediumThese initiatives aim at improving care of chronic dis-
eases by encouraging healthcare providers to coordinate
and integrate health services as well as to promote
patients’ self-management [6].
In Switzerland interest in CDM is recent, contrary to
North America and some European countries [7]. Switz-
erland, a federal state constituted of 26 cantons, has a
healthcare system characterized by a decentralized struc-
ture where each canton decides on the organization of
care [8]. Ambulatory care is mainly provided by inde-
pendent private practitioners and outpatient servicesntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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[9,10]. In 1990, integrated care organizations like phy-
sicians’ network and Health Maintenance Organiza-
tions were created [11]. Functioning on a gate-keeping
principle, these organizations reinforce the collabor-
ation between healthcare providers and promote qual-
ity circles and use of guidelines [12]. Moreover, CDM
initiatives have emerged within various settings [13,14]
but remain rare. In this context, we need to under-
stand barriers, facilitators and incentives to the imple-
mentation of CDM in Switzerland. The objective of
our study was thus to explore opinions of various
healthcare stakeholders on the development of CDM
programs in this country. We carried out a qualitative
study at national and cantonal levels to meet our aim.
Methods
Because of the exploratory nature of the study, qualita-
tive methods were used to collect and analyze the data.
Indeed, we combined individual interviews and focus
groups to explore opinions of Swiss healthcare stake-
holders on CDM. Data were then treated by a thematic
analysis.
Study population
We used a purposive sampling strategy to select partici-
pants that we thought to have knowledge and experience
of chronic diseases. Therefore, we defined the groups
of participants we intended to interview and did not
conduct individual interviews and focus groups up to
data saturation.
Individual interviews
To recruit healthcare stakeholders, we decided to con-
tact the following organizations acting at different levels
of the healthcare system:
– Ministry of health of various cantons
– Federal office of public health
– Health insurance companies
– Swiss medical association
– Swiss societies of medicine (general-internal
medicine, endocrinology-diabetology, pneumology
and cardiology)
– Cantonal societies of medicine
– Companies and physicians network with experience
in developing chronic disease management projects
– Institute of nursing
– Swiss society of pharmacist
– Home healthcare centres
– Patients’ organizations
Each group received a letter detailing the aims of the
study and asking them to give us the contact details of akey informant member interested to participate in our
study. Thirty-three individual interviews, each lasting ap-
proximately one hour, were conducted: 25 in French, 8
in German.
Focus groups
Chronic patients and medical staff were interviewed
using the method of the focus groups (FGs) which
allows the free debate of opinions [15]. Initially, we
planned to organize FGs with patients suffering from
diabetes, heart failure and chronic obstructive pul-
monary disease (COPD). However, because the ab-
sence of patients’ associations targeting the latter two
diseases and the lack of success of cardiologists and
pneumologists in recruiting these patients, we eventu-
ally renounced to organise these two focus groups.
We organized 5 FGs, each lasting approximately two
hours, as following:
– One FG with diabetic patients
– Two FGs with general practitioners (GPs)
– One FG with specialists (diabetologists,
pneumologists and cardiologists)
– One FG with nursing staff
To recruit diabetic patients, physicians and nurses,
we contacted the association of diabetic patients and
professionals association respectively. A letter was sent
to members of associations; those interested by our
study contacted us. Twenty-four patients agreed to par-
ticipate. We selected them on the basis of their avail-
ability and on characteristics such as the place of
residence, diabetes type, age or gender. Ten patients fi-
nally participated to our FG. Sixty seven professionals
contacted us and were selected on the basis of place
and number of years of practice. Finally, 23 profes-
sionals participated in our FGs. Patients and profes-
sionals received a letter detailing the aims of the study,
date, time and location of the FG.
All participants were assured that the data would be
confidential and anonymous. Approval was received
from the Ethics Committee on Research on the Human
Being of the canton of Vaud.
Data collection
An interview guide was developed and pilot-tested. It
consisted of open-ended questions on the following
main topics:
– Experience and quality of chronic care
– Means to improve chronic care
– Opinions on CDM programs
– Barriers and facilitators to the development of CDM
programs, incentives for participation.
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asked participants if they had previously heard about it.
If they did not know CDM, we briefly defined it. Indeed,
we explained that it was a means to eliminate care frag-
mentation, that it included patients’ self-management
and professionals’ teamwork, and that CDM programs
were based on formal evidence of effectiveness and were
adapted to patients’ needs. The latter point was illu-
strated with a figure of Kaiser’s triangle. For the FGs, we
also added a clinical vignette presenting the story of a
fictive patient benefiting from CDM.
The present study focuses only on the barriers, facilita-
tors and incentives to the development of chronic dis-
ease management programs.
Two researchers, specialized in qualitative research
methods, conducted the individual interviews and the
FGs between October 2009 and June 2010. All individual
interviews and FGs were audio-taped and transcribed
verbatim.
Data analysis
Analysis was carried out inductively, because of the ex-
ploratory nature of the study. Thematic analysis, used in
content analysis, was chosen to reduce the content of
discourses without loss or distortion of information.
Thematic analysis is also an appropriate method for ex-
ploring opinions by “identifying, analyzing and reporting
patterns (themes) within data” [16]. Transcripts were
first analyzed line by line and divided into sequences
representing themes (thematic sequences). Thematic
sequences about barriers, facilitators and incentives to
participation were then identified. They were finally clas-
sified according to several levels: political, financial,
organizational and structural, and professionals or
patients.
One researcher (SL) coded all transcripts. Checks of tran-
scripts codes and information exchange with the last author
(IPB) were regularly conducted so as to ensure consistency.
Presentation of the results
Results have been presented separately for each classifi-
cation level, always presenting barriers first, then facilita-
tors and incentives (when appropriate). We will refer to
barriers when people mentioned an existing element that
could impede CDM programs. Facilitators will refer to
an element that could either already exist or could be
implemented to facilitate CDM programs. Incentives
refer to elements that could motivate actors to partici-
pate to a program. Barriers, facilitators and incentives
could either be mentioned explicitly (in answer to our
questions) or implicitly, meaning that we considered the
discourse of our participants as possible barriers, facilita-
tors and incentives. The implicit elements will always be
specified and presented after those which are explicit.For each result, we mentioned which group(s) of partici-
pants was/were the source. They were categorized as
follows:
a) Patients (patients’ FG and the individual interview
with a representative of patients organization)
b) Physicians (FGs with GPs and specialists as well as
the individual interviews with members of : the
Swiss medical association, Swiss societies of
medicine and cantonal societies of medicine)
c) Nursing staff (nurses’ FG and the individual
interviews with nurses manager and administrators
of home healthcare)
d) Pharmacists (individual interview with a member of
the Swiss society of pharmacists)
e) Representatives of departments of public health
(DPH) (individual interviews with ministries of
health and with representatives of the federal office
of public health)
f ) Health insurers (individual interviews with health
insurers)
g) Companies proposing chronic disease management
programs (interviews with administrators of
companies and physicians’ networks that have
developed such projects)
Results
Generally, our results show that despite their different
positions and roles in the healthcare system, the stake-
holders mentioned similar barriers, facilitators and
incentives to the development of CDM in Switzerland.
Political level
Except for patients, all stakeholders mentioned the fed-
eralist political organization as a barrier to the develop-
ment of CDM programs in Switzerland because it gave
too much autonomy to the cantons in the organization
of healthcare. Thus, CDM would be difficult to imple-
ment at a national level because each canton functions
differently.
Extract
“(. . .)the problem is that our sanitary laws are
cantonal (. . .) if they were at a federal level (. . .) if we
said that the care is like this, it would be valid for
everyone, we could do the same in the whole of
Switzerland (. . .)but it’s not done at the federal level
(. . .)” (pharmacist)
To overcome this barrier, all participants, except nurs-
ing staff, proposed to set up a legal framework aimed at
facilitating the development of CDM. Patients, physi-
cians, health insurers and DPH also emphasized the im-
portance of a cantonal application of such a legal
Lauvergeon et al. BMC Health Services Research 2012, 12:176 Page 4 of 9
http://www.biomedcentral.com/1472-6963/12/176framework, to adapt CDM programs to loco-regional
specificities.
The general opinion of participants on CDM (in
favour or not) could also be viewed as either a barrier or
a facilitator. Indeed some physicians, insurers and DPH
were sceptical about the necessity of implementing
CDM in Switzerland, for three reasons. Firstly, they
mentioned that CDM had been implemented in coun-
tries where it was necessary to change healthcare system
because of a lack of healthcare structures. Conversely,
Switzerland possessed many local healthcare structures
and did not need to change its system.Extract
“(. . .) In the United-States, contrary to Switzerland,
there are lots of patients who are coached for distance
reasons, because they don’t have a hospital on each
street corner like us, in Switzerland we rather have an
excessive offer (. . .)” (Health insurer)
Secondly, they specified that care in Switzerland was
already adapted to patients’ needs and disease severity,
as proposed in CDM programs. Thirdly, they mentioned
that work in multidisciplinary teams already occurred in
informal network (that is, the personal network of the
physician). Thus, CDM was only seen as a means to
formalize what already exists.
At the same time, all participants were in favour of
CDM considering that Switzerland possessed all the ne-
cessary resources for its implementation. The groups of
physicians, nursing staff, DPH and companies proposing
CDM programs noted that the main actors were awareTable 1 Political barriers and facilitators to CDM developmen
Patients Physicians
Barriers Federalist political
organisation
x
Scepticism about the
necessity of CDM
x
Facilitators Legal framework to
CDM development
x x
Loco-regional application
of the framework
x x
Favorable opinions
towards CDM
x x
Availability of
existing resources
x x
Awareness of actors
towards current
chronic care problems
(with development of
CDM initiatives)
xof the problems of current chronic care. They men-
tioned the development of several initiatives aiming to
improve chronic care, even if they occurred at a loco-
regional level and had been more broadly developed in
the German part of Switzerland.
At the political level, we found no themes that we
could consider as incentives. Results were summarized
in Table 1.Financial level
All participants mentioned financial barriers. They
raised the problem of who can pay for CDM because
some components (such as prevention, self-management
education or coordination for teamwork) are currently
not easily reimbursed by health insurance companies.Extract
“(. . .)To try to find possibilities to reimburse
coordination services of (. . .) that is very difficult, it
doesn’t fit in the reimbursement system (. . .), it’s very
difficult to find solutions for these coordination
services which are not medical services (. . .)how can
we justify that we pay for something which is in the
background?(. . .)” (DPH)
As facilitator to CDM development, all stakeholders,
except patients and pharmacists, wanted to have proofs
that CDM is cost effective. Moreover, health insurers
should adopt a long term vision and reimburse programs
(according to patients, physicians, health insurers, DPH).
Nevertheless, patients, DPH and companies proposing
CDM programs estimated that it would be difficult tot by group of participants
Nursing
staff
Pharmacists Health
insurers
DPH Companies
proposing
CDM prog.
x x x x x
x x
x x x x
x x
x x x x x
x x x x x
x x x
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CDM programs since they are not integrated in the basic
health insurance package. Moreover, the present risk
compensation scheme encourages health insurance com-
panies to select low risk patients rather than attract
patients with chronic diseases. To avoid this problem
and create incentive for health insurers, improvement of
the Swiss health insurance compensation scheme was
proposed.
Extract
(Speaking about what could be done to motivate
health insurance companies to participate in CDM) “
(. . .) It's modifying risk compensation so that health
insurances are interested to do this kind of thing, that
is, are also interested to have chronic patients or more
expensive patients with them (. . .)" (Patients)
Other answers of our participants could be also viewed
as barriers as well as facilitators. Patients, physicians,
nursing staff, DPH and companies proposing CDM
programs disagreed on the economic impact of CDM
programs. While some considered that CDM would
reduce health costs (by decreasing the number of
hospitalization thanks to prevention activities), others
imagined that CDM would increase health costs because
of costs related to the implementation process of CDM
programs, and to increasing patients’ life expectancy. Fi-
nally, some did not expect changes in healthcare costs,
and others (pharmacist and DPH) mentioned that costTable 2 Financial barriers, facilitators and incentives to CDM
Patients Physicians
Barriers Who can pay for CDM x x
Costs increasing with
CDM development
x
Cost decreasing in HMO
due to risk selection
Lack of motivation of health
insurer to reimburse CDM
x
Facilitators Proofs of cost-effectiveness
of CDM
x
Reimbursement of CDM
components by
health insurance
companies adopting
long term vision
x x
Costs decreasing with
CDM development
x x
Cost stability x
Incentive Better risk
compensation scheme
to motivate health insurances
to reimburse CDM
xreductions observed in Swiss HMO could be explained
by risk selection. Results were summarized in Table 2.Organizational and structural levels
Nursing staff and DPH cited the fear of transparency as
a barrier, because institutions did not want to publicly
show their data.Extract
“(. . .) When we want to show the outcomes (. . .)
everyone is afraid (. . .) and here there are certainly
barriers (. . .) we don’t want to be transparent (. . .)
there is a deep anxiety to show how it goes here (. . .)
we have to do an evaluation, we know that when we
have the financing in one hand (. . .) and in the other
hand a transparency in outcomes, things change very
quickly (. . .)” (Nurses)
The lack of statistics on chronic disease patients was
also raised by physicians and DPH as a barrier to the de-
velopment of CDM.
The stakeholders did not mention solutions to over-
come each of these barriers. They nevertheless evoked
some facilitators at the organizational and structural
levels’. Indeed, according to patients, physicians, nursing
staff and DPH, CDM should be implemented within
existing care structures, such as home healthcare or
patients’ association, because they shared common pro-
gram elements (teamwork for example).development by group of participants
Nursing
staff
Pharmacists Health
insurers
DPH Companies
proposing
CDM prog.
x x x x x
x
x x
x x
x x x x
x x
x
x x x
x x
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independently by healthcare professionals and not with
an economic perspective by health insurers. Physicians,
nursing staff and DPH also expressed the need to clearly
define the stages and functioning of CDM programs.
At the organizational and structural levels, the partici-
pants’ positive attitude towards CDM can be considered as
a facilitator to CDM development. Indeed, some described
CDM as a means to improve quality of care through better
comprehensive care as well as a means to favour commu-
nication between hospitals and ambulatory care services.
Also all participants except nursing staff and pharmacists
considered that CDM would encourage, within care orga-
nizations, the setting up of electronic medical records or
phone consultations, as well as the use of guidelines.Extract
"(. . .) so it means (. . .) to change the services that are
provided (. . .) I mean we know the best practices in
diabetics' care, we have them, why are they not
implemented? (. . .)" (DPH)
No incentives were mentioned at the organizational and
structural levels. Results were summarized in Table 3.Professionals’ level
Physicians, nursing staff and DPH mentioned that the
supposed and feared rigidity of the CDM programs would
curtail the current autonomy and freedom of practice.
The loss of autonomy was considered as a barrier to
CDM development. These participants, with companies
proposing CDM programs, added the barrier of the “cor-
poratism” which led to the “compartmentalization” of dis-
ciplines, and thus, impeded collaboration. All participants,
except pharmacists and DPH, also mentioned the barrier
of the shortage of physicians as well as the problem of the
ratio of general practitioners/specialists in rural regions.
Finally stakeholders, except patients and physicians, alsoTable 3 Organizational and structural barriers and facilitators
Barriers Fear of data transparency
Lack of statistics on chronic disease patients
Facilitators Development of CDM on the basis of existing structure
Independent management of CDM by health care professionals
Clear stages and functioning of CDM
Positive attitude to CDM
Comprehensive care with CDM
Improved coordination between hospital and ambulatory care
Setting of tools and use of guidelines within CDMnoted actors’ inertia and lack of interest leading to slow
decisions and reluctance to change.
As facilitators, pharmacists, DPH and companies pro-
posing CDM programs expressed the need of a change
in mentality and culture. According to nursing staff,
insurers, DPH and companies proposing CDM pro-
grams, a common will of all the actors involved in care
would also be necessary.
Extract
“(. . .) we have all the infrastructure to do anything
(. . .) but it has to become the custom, the practise (. . .)
it has to reach everyone, all the actors and patients
and it will certainly take time (. . .) everything take
time here (laugh) it needs a real willpower (. . .) not
only politic, of all the actors (. . .)” (Health insurer)
To facilitate the coordination of all professionals
involved in care, physicians, health insurers, DPH and
nursing staff, emphasized that the role of each professional
should be defined. All the participants except patients and
pharmacists also expressed the need to designate a care
coordinator. According to physicians, health insurers and
DPH, this coordinator should ideally be the GP. In any
case, the healthcare professionals participating in CDM
program should be trained to the functioning of CDM
programs and to work in team. However, almost all parti-
cipants considered that it would be difficult to motivate
physicians to participate in CDM, especially older GPs
who are used to work independently.
Extract
"(. . .) physicians are individualist maniacs, physicians
alone in their surgery since 25 years who are over
55 years old, it will be difficult to integrate them in
such systems (. . .)" (Physicians)
To motivate healthcare professionals to participate in
CDM programs, three types of incentives were proposed.to CDM development by group of participants
Patients Physicians Nursing
staff
Pharmacists Health
insurers
DPH Companies
proposing
CDM prog.
x x
x x
x x x x
x
x x x
x x x x x x x
x x x x
x x x
x x x x x
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tions: the certainty that CDM improves quality of care,
the possibility for physicians to have a help with their
work load (thanks to the task delegation), and to have
practical experience of a CDM program as well as to
participate in its implementation and development.
Teamwork and quality circles could also motivate pro-
fessionals by breaking loneliness and giving the oppor-
tunity to exchange experience. The second incentive,
financial, was extensively discussed by participants. In-
deed they evoked this form of incentives even if some
feared that it could only motivate people for economic
reasons. However, in any case, participants said that
quality incentives should prevail over financial incen-
tives. The third incentive aimed at resolving the problem
of financial incentives by integrating CDM components
into the services usually provided by healthcare profes-
sionals (according to physicians, nursing staff and DPH).
Results were summarized in Table 4.Patients’ level
Participants did not mention barriers at this level,
expecting that patients would favour CDM. They also
mentioned the program’s adaptation to patients’ needs
as a facilitator to CDM development.
Extract
"(. . .) The program would be an assessment, first we see
where the patient is, where potentials are (. . .) and after-
wards (there is) an education targeted on gaps (. . .) so
that's very important, first an assessment and then to
come to an agreement with the patient on what he wants
to change (. . .)" (companies proposing CDM programs)Table 4 Barriers, facilitators and incentives to CDM developm
P
Barriers Lack of autonomy and freedom of practise with CDM
Corporatism
Shortage of physicians and inappropriate GP/specialists ratio x
Inertia with lack of interest
GP’s lack of motivation
Facilitators Mentality and culture change to accept CDM
Common will
Definition of the role of each professionals’
Designation of a care coordinator
GP as the care coordinator
Availability of CDM training x
Incentives Quality incentives x
Financial incentives x
Integration of CDM into services usually reimbursedParticipants, except companies proposing CDM pro-
grams, also proposed to reinforce patients’ own responsibil-
ity in their care. An increased supply of self-management
classes were thus proposed by all participants except phar-
macists. Physicians and companies proposing CDM pro-
grams emphasized the importance of checking that patients
understood correctly the information received.
However, physicians, nursing staff and companies pro-
posing CDM programs considered that it would be difficult
to change patients’ habits. To motivate patients, our parti-
cipants suggested quality incentives such as CDM informa-
tion, awareness of CDM benefits and assurance that
patients would always be in touch with the same profes-
sionals. The possibility to integrate a support group was
also mentioned. All participants, except patients and phar-
macists, also evoked financial incentives. Indeed, nursing
staff and DPH found that the financial aspects of care were
important for patients. By contrast, physicians and health
insurers expressed their scepticism about the effectiveness
of such incentives because, according to them, they could
lead to patients’ participation to CDM for economic rea-
sons, or to a “two-speed healthcare”, with some patients
preferring to pay more for having free choice of care.
Extract
“(. . .) Financial incentives raise social problems because
(. . .) if we propose a discount to someone that earns a lot
of money, he doesn’t care, but if you propose this discount
to someone who doesn’t earn a lot of money and who has
children, it’s not an option anymore, it becomes an ob-
ligatory choice, and thus, the free choice is emptied of its
sense (. . .)” (physicians)
Results were summarized in Table 5.ent by group of participants at the professionals’ level
atients Physicians Nursing
staff
Pharmacists Health
insurers
DPH Companies
proposing
CDM prog.
x x x
x x x x
x x x x
x x x x x
x x x x x
x x x
x x x x
x x x x
x x x x x
x x x
x x x x
x x x x x x
x x x x x x
x x x
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Our results show that the various healthcare stake-
holders mentioned similar barriers, facilitators and
incentives to the development of chronic disease man-
agement (CDM) in Switzerland at a political, financial,
organizational-structural, professionals and patients
level.
Given that the main identified barrier to CDM devel-
opment is the problem of the federalist organization of
Switzerland, it would be difficult to implement CDM na-
tionally, as did some countries with national healthcare
systems. Indeed the literature shows that national deci-
sions facilitate the development of CDM [4]. CDM
initiatives were thus implemented at national levels in
the UK (for instance, community matrons for older
complex chronic people) and more recently at a very
large scale, in Germany. In this country, since 2003,
health insurers have been encouraged to develop CDM
programs, and incentives were created to facilitate the
participation of patients and primary care physicians
[17]. However, CDM has also been developed for several
years at regional levels, in countries such as the Nether-
lands, the USA and Canada, and more recently in others
in Europe [4]. A federalist political organization could
also be viewed as a chance to implement CDM pro-
grams adapted to loco-regional specificities. This
explains why our participants recommended a cantonal
application of the legal framework.
The second barrier mostly evoked by our participants,
and often cited by authors is the problem of who could
pay for CDM [18], because its components are assimi-
lated to management, coordination and prevention activ-
ities currently not reimbursed. In fact, our participants
considered that the cost-effectiveness of CDM needs to
be proved to convince health insurers to reimburse
CDM and healthcare stakeholders of its utility. Indeed,
our participants were themselves not convinced by the
cost-effectiveness of CDM. Studies have shown that cost
saving depends on the disease targeted, the institutionTable 5 Barriers, facilitators and incentives to the developme
Pati
Barrier Difficulties to change patients’ habits
Facilitators Supposition of a favourable opinion of patients on CDM
Adaptation of CDM to patients needs x
Reinforcement of patients’ responsibility in care x
More self-management education classes x
Check the patients’ understanding of information
Incentives Quality incentives x
Financial incentiveswhere CDM is implemented and the mode of payment,
so clear evidence on costs reduction with CDM are cur-
rently lacking[19-21].
Finally, our participants often tackled the issue of
patients’ and professionals’ participation to CDM, and of
participation incentives. Others have shown that quality
incentives could encourage healthcare professionals to
participate [3] in particular the conviction that CDM
improves quality of care [22] or that teamwork, a com-
ponent of CDM, is beneficial [23]. Our participants
raised doubts about the efficacy of financial incentives,
which have been shown to have limited impact especially
on the physicians’ participation to CDM [24]. There are
unfortunately few studies that explored opinions on
patients’ motivation and incentives for their participation
to CDM or to one component of CDM [25].
The stakeholders interviewed did not mention the im-
portance of leadership as a facilitator to CDM. This con-
trasts with other studies [26-28] exploring this issue
within institutions where CDM had already been imple-
mented. In fact, the only stakeholder that has spoken
about leadership in our study was one of the participants
who had implemented CDM in his organization.
The strength of our study is that we provided the opi-
nions of various healthcare stakeholders on the develop-
ment of CDM. Therefore, this multiplicity of points of
views represents a great opportunity to better under-
stand barriers, facilitators and incentives to CDM. This
should be of interest both for Switzerland and other
countries facing the challenge of improving care for
chronic diseases, especially since opinions converged in
several ways. Two limitations of this study need to be
considered. First, some participants were not familiar
with CDM and may have misunderstood what it repre-
sented, despite preliminary explanations during the
interview. Since CDM development in Switzerland is in
its infancy, some participants may have had difficulties
to imagine the practical developments of something
which was, for them, too theoretical. Second, went of CDM by group of participants at the patients’ level
ents Physicians Nursing
staff
Pharmacists Health
insurers
DPH Companies
proposing
CDM
x x x
x x x
x x x x x x
x x x x x
x x x x x
x x
x x x x x x
x x x x x
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our results cannot allow generalization to all Swiss
healthcare stakeholders. However, the aim of a purposive
sampling strategy is to select people with various charac-
teristics relevant to the study objective. Qualitative re-
search also aims to explain in details the phenomenom
studied, not to provide representative results.
Conclusions
Despite their different role and interest regarding chronic
diseases, healthcare stakeholders suggested similar barriers,
facilitators and incentives to the development of CDM
programs in Switzerland. These common opinions and
their overall positive attitude towards CDM suggest that it
could be further implemented if political, financial and
organizational barriers as well as the scepticism and non-
motivation of some stakeholders were overcome.
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